

1 **Inducible cell-specific mouse models for paired epigenetic and transcriptomic studies of**
2 **microglia and astroglia**

3 **Authors:** Ana J. Chucair-Elliott,¹§ Sarah R. Ocañas,^{1,2}§ David R. Stanford,¹ Victor A. Ansere,^{1,2}
4 Kyla B. Buettner,^{1,2} Hunter Porter,^{1,3} Nicole L. Eliason,⁴ Justin Reid,⁵ Amanda L. Sharpe,⁴
5 Michael B. Stout,⁶ Michael J. Beckstead,⁵ Benjamin F. Miller,⁵ Arlan Richardson,^{7,8} Willard M.
6 Freeman^{1,8*}

7 ¹Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City,
8 OK USA. ²Department of Physiology, University of Oklahoma Health Sciences Center,
9 Oklahoma City, OK USA, ³Oklahoma Center for Neuroscience, University of Oklahoma Health
10 Sciences Center, Oklahoma City, OK USA, ⁴Department of Pharmaceutical Sciences, University
11 of Oklahoma Health Sciences Center, Oklahoma City, OK USA, ⁵Aging & Metabolism Program,
12 Oklahoma Medical Research Foundation, Oklahoma City OK USA, ⁶Department of Nutritional
13 Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK
14 USA, ⁷Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma
15 City, OK, USA, ⁸Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK USA

16 **To whom correspondence should be addressed:** ^{*}Willard M. Freeman, Genes & Human
17 Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma
18 City, OK 73104, USA.

19 **Tel:** 405-271-3139

20 **Fax:** 405-271-2536

21 **E-mail address:** bill-freeman@omrf.org

22 [§]*These authors contributed equally*

23 **Abstract**

24 Epigenetic regulation of gene expression occurs in a cell type-specific manner. Current cell-type
25 specific neuroepigenetic studies rely on cell sorting methods that can alter cell phenotype and
26 introduce potential confounds. Here we demonstrate and validate a Nuclear Tagging and
27 Translating Ribosome Affinity Purification (NuTRAP) approach for temporally controlled labeling
28 and isolation of ribosomes and nuclei, and thus RNA and DNA, from specific CNS cell types.
29 Paired analysis of the transcriptome and DNA modifications in astrocytes and microglia
30 demonstrates differential usage of DNA methylation and hydroxymethylation in CG and non-CG
31 contexts that corresponds to cell type-specific gene expression. Application of this approach in
32 LPS treated mice uncovers microglia-specific transcriptome and epigenome changes in
33 inflammatory pathways that cannot be detected with tissue-level analysis. The NuTRAP model
34 and the validation approaches presented can be applied to any CNS cell type for which a cell
35 type-specific cre is available.

36 Introduction

37 Significant advances are being made in understanding the epigenome and its relationship with
38 gene expression in the brain¹⁻³. However, the lack of approaches for paired analysis of DNA and
39 RNA profiles at the cell type-specific level within the same animal is a significant limitation for the
40 field, given that epigenetic processes differ across CNS cell types at the level of chromatin
41 organization and DNA modifications^{1,4}. Obtaining enriched cell populations by flow sorting
42 requires cell surface markers but these markers can change with experimental conditions and cell
43 sorting causes molecular, morphological, and functional changes, such as cell activation, that
44 could confound studies^{3,5,6}. Single cell approaches⁷ may overcome some of the challenges of
45 cell sorting but the scale of such studies, partial genomic coverage, restriction to only certain types
46 of endpoints, and continued potential for brain dissociation artifacts are limitations.

47 This has led to development of transgenic labeling approaches to isolate RNA or DNA from
48 specific cell types. Ribosome labeling and RNA isolation methods, such as Translating Ribosome
49 Affinity Purification (TRAP⁸), and ribosome tagging (RiboTag⁹), are gaining acceptance across
50 neuroscience studies examining the transcriptome. Similar approaches have been developed to
51 transgenically tag and allow isolation of nuclei and thus DNA (Isolation of Nuclei TAGged in
52 Specific Cell Types, INTACT)¹⁰. However, using separate transgenic mouse strains for DNA and
53 RNA endpoints is a complicated and resource intensive approach.

54 Here we describe an approach where Nuclear Tagging and Translating Ribosome Affinity
55 Purification (NuTRAP)¹¹ is combined with well-established cell-specific inducible cre-recombinase
56 expressing systems^{12,13} to perform paired transcriptomic and epigenomic analyses of specific
57 CNS cell types in a temporally controllable manner from a single mouse. Demonstration studies
58 with astrocytes and microglial provide: 1) cell type-specific enrichment of RNA and DNA, 2) novel
59 insights into differential usage of DNA modifications in microglia and astrocytes, and 3) examples
60 of cell-type specific transcriptomic and epigenomic responses that are only revealed when specific
61 cell types are examined. These studies also provide a validation approach NuTRAP mouse lines
62 crossed to any available cre driver line relevant to neuroscience studies.

63 **Results**

64 Schematics of the NuTRAP construct, experimental design, and key protocols for the analyses in
65 the current study are represented in **Supplemental Figure 1**. Of note, the Aldh111-cre/ERT2;
66 NuTRAP and Cx3cr1-cre/ERT2; NuTRAP models will be abbreviated when necessary, as
67 Aldh111-NuTRAP and Cx3cr1-NuTRAP, respectively. Testing of Tamoxifen (Tam) administration,
68 for cre induction, effects on the epigenome and transcriptome in the CNS found no long-lasting,
69 significant effects on DNA modifications or gene expression¹⁴.

70 **Flow cytometry and immunohistochemical validation of the Aldh111-cre/ERT2⁺; NuTRAP⁺** 71 **mouse brain.**

72 The Aldh111-cre/ERT2⁺ mouse line has been reported as highly efficient and specific for DNA
73 recombination in astrocytes¹². We first crossed this line with the NuTRAP reporter mouse¹¹ to
74 couple epigenomic and gene expression studies in astrocytes in a parallel fashion. As an initial
75 validation of the model, Aldh111-NuTRAP mice were systemically delivered Tam for 5 consecutive
76 days and a week after induction, brains were dissected for flow cytometry (FC) and
77 immunohistochemistry (IHC) analyses. Single-cell suspensions of brains immunostained with
78 ACSA-2 antibody, a pan-astrocytic marker¹⁵, revealed a distinct EGFP⁺ cell population present in
79 the Aldh111-NuTRAP brains but not in the cre negative counterparts, consistent with the reported
80 10-20% astroglial cellularity in the rodent brain^{16,17}. Almost the entirety of the EGFP⁺ cell
81 population co-expressed ACSA-2, supporting that cre-mediated recombination upon Tam
82 induction specifically targeted astrocytes (**Figure 1A-B**).

83 Sagittal brain sections immunostained with cell-specific markers showed EGFP and mCherry
84 colocalization in cells expressing the astrocytic marker GFAP, but not in cells expressing
85 microglial (Cd11b), or neuronal (NeuN) markers (**Figure 1C, Supplemental Figure 2**). In the
86 absence of Tam induction Aldh111-NuTRAP mice did not display EGFP or mCherry expression
87 (**Supplemental Figure 2**), consistent with temporally-controlled, Tam-dependent induction of cre-
88 recombinase under the control of the Aldh111 promoter.

89 **Astrocyte transcriptome enrichment in the Aldh111-NuTRAP mice by TRAP-RNAseq.**

90 Enrichment of EGFP-tagged polysomes was performed with the TRAP protocol. The resulting
91 positive and negative fractions, as well as input fraction, were collected for RNA isolation. qPCR
92 measurements showed significant enrichment of marker genes for astrocytes (Aldh111 and GFAP)
93 in the positive fraction compared to input and negative fractions. Depletion of marker genes for

94 microglia (Cx3cr1, C1q, Itgam), neurons (Eno2, Npas4), and oligodendrocytes (Mog) was
95 observed in the positive TRAP fraction compared to the other fractions (**Figure 2A**). RNAseq
96 analysis, as visualized by Principal Component Analysis (PCA), revealed separation of positive
97 fraction from input, negative, and whole tissue samples in the first component (**Figure 2B**). Cell
98 type-specific marker gene lists were generated from prior cell sorting studies¹⁸ (**Supplemental**
99 **Table 4**). The distribution of cell type-specific gene expression showed enrichment of astrocytic
100 genes and depletion of microglial, neuronal, and oligodendrocytic genes in the positive fraction
101 relative to input (**Figure 2C-2D**).

102 One prior study applied the RiboTag approach with the same Aldh111- cre/ERT2 line of mice¹². In
103 another recent study¹⁹ the RiboTag approach with a Gfap-cre was used to target the astrocyte
104 transcriptome. We compared the lists of astrocyte marker genes (BHMTc p<0.05, FC enrichment
105 >5) generated in these studies with the data from the NuTRAP line developed here and found
106 127 ribosomal-tagging marker genes for astrocytes that are independent of ribosomal tagging
107 approach or cre line (**Figure 2E, Supplemental Table 4**). When this list of 127 ribosomal-tagging
108 astrocyte marker genes was compared to previously-identified astrocyte markers from cell sorting
109 studies¹⁸, we found 12 isolation method independent astrocyte marker genes (**Figure 2F,**
110 **Supplemental Table 4**). Taken together, these comparisons demonstrate a commonality to
111 astrocyte enriched genes with some minor differences in RiboTag versus NuTRAP and Aldh111
112 versus Gfap cre lines. Astrocyte enriched transcripts further demonstrated over-representation of
113 genes critical in astrocyte physiological functions^{12,19,20} such as cholesterol synthesis and
114 transport, fatty acid metabolism, receptors/channels, complement/immune mediators and
115 synapse modification (formation, function, and elimination) (**Supplemental Figure 3**). These
116 findings are collectively in agreement with the normal physiology of astrocytes in the brain and
117 demonstrate specific targeting and enrichment of astrocyte transcripts in the Aldh111-NuTRAP
118 model.

119 **Validation of astrocytic epigenome enrichment in the Aldh111-NuTRAP mouse brain by** 120 **INTACT-BSAS.**

121 Nuclear preparations of Aldh111-NuTRAP were subjected to INTACT isolation with streptavidin
122 magnetic beads for separation of negative and positive (biotinylated) nuclei. To assess purity of
123 putatively astrocytic nuclei in the positive fraction, nuclei were evaluated for expression of
124 mCherry by confocal microscopy imaging (**Figure 3A-B**). Biotinylated, mCherry⁺ nuclei covered
125 by streptavidin beads (that fluoresce in the red channel¹⁰) were evident in the positive fraction
126 (**Figure 3A**) and comprised 90% of the positive fraction (**Figure 3B**). With the predicate that mCG

127 in gene promoters is inversely related to transcriptional activation, Bisulfite Amplicon Sequencing
128 (BSAS) analysis was performed to measure the percentage genomic CG methylation (mCG) in
129 the promoter region of selected astrocytic (Fabp7), microglial (Gpr84), and neuronal (Eno2)
130 marker genes (**Figure 3C**). In the positive fraction, hypomethylation of the Fabp7 gene promoter
131 as compared to input and negative fractions correlated with increased gene expression found by
132 RNAseq (**Figure 3D**), supporting the astrocytic identity of the INTACT-isolated nuclei and DNA in
133 the positive fraction. A minor trend to mCG hypermethylation of the non-astrocytic gene promoters
134 Gpr84 and Eno2 coincided with depletion of microglial and neuronal gene expression in the
135 positive fraction.

136 **Flow cytometry and immunohistochemical validation of the Cx3cr1-cre/ERT2⁺; NuTRAP⁺** 137 **mouse brain.**

138 Validation of the Cx3cr1-NuTRAP line was performed with a similar approach as above. Tam was
139 administered for 5 consecutive days and in order to avoid labeling of circulating monocytes in the
140 tissue, which unlike resident microglia are short-lived and rapidly renew themselves²¹, brain tissue
141 collection was delayed until 3-4 weeks after treatment. Single cell suspensions of brain tissue
142 immunostained with antibody against CD11b, a microglia marker, revealed a distinct EGFP⁺ cell
143 population present in the Cx3cr1-NuTRAP brains but not in the cre negative subjects, consistent
144 with the reported 5-10% microglial constituency of the mouse brain²². The EGFP⁺ cell population
145 almost completely co-expressed CD11b, evidence of cell-specific cre recombination for the
146 microglial lineage (**Figure 4A-B, Supplemental Figure 4**). The evidence for microglia-specific
147 recombination was next tested with IHC. Sagittal brain sections immunostained with cell-specific
148 markers showed EGFP and mCherry colocalization in cells expressing CD11b (**Figure 4C,**
149 **Supplemental Figure 4**). In the absence of Tam induction, FC immunolabelings indicated that
150 Cx3cr1-NuTRAP mice displayed a small EGFP⁺ cell population that mostly expressed CD11b.
151 Such observation was in agreement with reported findings using the same cre line⁵, and was not
152 clearly detected with the sensitivity of IHC (**Supplemental Figure 5**).

153 **RNAseq validation of microglial transcriptome enrichment in the Cx3cr1-NuTRAP mouse** 154 **brain by TRAP-RNAseq.**

155 TRAP isolation was performed as described above. Initial qPCR validation of the TRAP-isolated
156 RNA from all three fractions showed significant enrichment of marker genes for microglia (Cx3cr1,
157 C1q, and Itgam) in the positive fraction compared to input and negative fractions. Significant
158 depletion of marker genes for astrocytes (GFAP and Aldh111) and oligodendrocytes (Mog), as

159 well as a trend in neurons (Eno2 and Npas4), was observed in the positive TRAP fraction
160 compared to the other fractions (**Figure 5A**). RNAseq was performed on input, negative, and
161 positive fractions from TRAP isolation, as well as whole tissue. Transcriptome profiles revealed
162 separation of positive fraction from all other groups (**Figure 5B**) by PCA. Fold change enrichment
163 in the positive TRAP fraction versus the input was compared to microglial marker genes lists from
164 cell sorting studies. Enrichment of microglial genes and depletion of astrocytic, neuronal, and
165 oligodendrocytic genes was observed in the positive fraction relative to input (**Figure 5C-5D**). The
166 same Cx3cr1-cre/ERT2(Jung) line as used here has been used with RiboTag enrichment of
167 microglial RNA⁵. In another study, the Cx3cr1-creErt2/(Litt) line was crossed with a TRAP mouse
168 model³. We compared the lists of microglial marker genes with FC>5 ($p<0.05$, positive
169 fraction/input) in these studies^{3,5} with the Cx3cr1-NuTRAP (Present study). We identified 142
170 ribosomal-tagging common microglial marker genes (**Figure 5E, Supplemental Table 5**).
171 Comparing the ribosomal-tagging microglial marker genes with previously established microglial
172 marker genes from cell sorting studies¹⁸ revealed 101 isolation method-independent microglial
173 marker genes (**Supplemental Table 5**).

174 Genes enriched in the microglia transcriptome included an overrepresentation of genes regulated
175 by PU.1 (also known as Spi1), a transcription factor that shapes the homeostatic functions of
176 microglia²³ (**Supplemental Figure 5**). Collectively, data provide ample support that the Cx3cr1-
177 NuTRAP model is suitable for studying the microglia transcriptomic signatures of the brain in both
178 homeostatic and stress settings.

179 Transcriptome comparison between Aldh1l1-NuTRAP and Cx3cr1-NuTRAP positive fractions by
180 regulator and pathway analyses confirmed cell-specific enrichments in agreement with brain
181 astrocytes and microglia, respectively (**Supplemental Figure 6**).

182 **Validation of microglial epigenome enrichment in the Cx3cr1-NuTRAP mouse brain by** 183 **INTACT-BSAS.**

184 In parallel with the TRAP protocol described above, nuclear preparations of Cx3cr1-NuTRAP
185 were subjected to INTACT isolation with streptavidin magnetic beads for separation of negative
186 and positive (biotinylated) nuclei. To assess purity of putatively microglial nuclei in the positive
187 fraction, nuclei were evaluated for expression of mCherry by confocal microscopy imaging.
188 Biotinylated, mCherry+ nuclei were covered by streptavidin beads (**Figure 6A**) and reached over
189 90% purity in the positive fraction (**Figure 6B**). CG methylation around the promoter region of
190 selected astrocytic (Fabp7), microglial (Gpr84), and neuronal (Eno2) genes (**Figure 6C**)

191 demonstrated hypomethylation of the Gpr84 gene promoter correlated with increased gene
192 expression levels assessed by RNAseq in the positive fraction (**Figure 6D**), as compared to input
193 and negative fractions was indicative of the microglial identity of the nuclei isolated in the positive
194 fraction by INTACT. In addition, we observed no significant change in the cytosine methylation of
195 Fabp7 and Eno2 gene promoters associated with depletion of astrocytic and neuronal gene
196 expression in the positive fraction.

197 **Cell-specific epigenetic findings by Whole Genome Oxidative Bisulfite Sequencing** 198 **comparing Aldh111-NuTRAP and Cx3cr1-NuTRAP models.**

199 The landscape of the brain epigenome at a single-base resolution, and at the cell type-specific
200 level, remains largely unknown^{2,24}. Moreover, no studies have compared the methylome of
201 different cell types, such as astrocytes and microglia, using a combination of inducible cre-
202 recombinase and NuTRAP technologies. Upon validation of the cell-specific identity of the
203 INTACT-isolated gDNA from positive fractions by BSAS (**Figure 3** and **Figure 6**), WGoBS
204 sequencing libraries were constructed from the DNA samples isolated from input, negative, and
205 positive INTACT fractions. Genome-wide levels of mCG, hmCG, mCH, and hmCH (see
206 **Supplemental Figure 7** for conversion efficiency controls) were compared across fractions and
207 cell types. The analysis revealed that global mCG levels are similar (~70%) between the Aldh111-
208 NuTRAP and Cx3cr1-NuTRAP positive fractions (**Figure 7A**). Of interest, levels of hmCG were
209 lower in the Cx3cr1-NuTRAP positive fraction and mCH levels were lower in both positive fractions
210 as compared to input and negative fractions (**Figure 7B-C**). These data demonstrate that
211 microglia use less cytosine hydroxymethylation compared to other cell types including astrocytes
212 (**Figure 7B**). The analysis of mCH levels showed a significantly lower level of mCH in the Aldh111-
213 NuTRAP and Cx3cr1-NuTRAP positive fractions with respect to their negative fractions. The lower
214 level of non-CG methylation was more pronounced in microglia, being significantly less than the
215 input. This is consistent with the concept that mCH is concentrated in neurons¹ and provides more
216 specific detail that this is true when astrocytes or microglial alone are examined. As previously
217 reported for the brain^{14,25,26}, no non-CG hydroxymethylation (hmCH) was detected in any of the
218 samples analyzed (**Figure 7D**). To uncover potential cell type-specific differences in mCG
219 patterns, methylation across cell-type marker genes (from -4kb in respect to the TSS and +4b
220 from the TES) was compared for astrocytes (**Figure 7E**) and microglia (**Figure 7H**). In Aldh111-
221 NuTRAP INTACT positive fractions, but not Cx3cr1-NuTRAP INTACT positive fractions,
222 hypomethylation upstream, within, and downstream the gene body (**Figure 7F**) was evident
223 across astrocyte marker genes as compared to input and Cx3cr1-NuTRAP positive fractions. This

224 correlates with the higher levels of mRNA expression of these genes in Aldh1l1-NuTRAP TRAP
225 positive fraction (**Figure 7G**). Similarly, only in the Cx3cr1-NuTRAP INTACT positive fraction,
226 hypomethylation upstream, within, and downstream the gene body of microglial markers genes
227 was evident (**Figure 7I**) and in agreement with higher mRNA expression of these genes in
228 microglia (**Figure 7J**).

229 CG dinucleotides are found far less frequently than other dinucleotide pairs (<1% dinucleotide
230 pairs) and are clustered together in CpG islands. Definitions for the regions around the CpG
231 islands have been established and include shores (2Kb upstream and downstream from CpG
232 island) and shelves (2Kb upstream and downstream from shores). Despite their high CG content,
233 CpG islands are mainly unmethylated while methylation is higher in shores and shelves²⁷.
234 Analysis of methylation and hydroxymethylation levels covering CpG islands, shores, and shelves
235 revealed that the shores and shelves of Cx3cr1-NuTRAP INTACT positive fractions cells had
236 significantly higher mCG levels (**Supplemental Figure 8 A-B**) and significantly lower hmCG
237 levels (**Supplemental Figure 8 C-D**) compared to the other groups. The findings allow us to
238 speculate that while low levels of mCG and hmCG are conserved in CpG islands across the
239 genome, epigenetic signatures found in shores and shelves might differentiate microglia from the
240 other cell types of the brain.

241 More than two-thirds of the mammalian genome consists of repetitive elements²⁸, including long
242 terminal repeats (LTR), long interspersed nuclear elements (LINE), short interspersed nuclear
243 elements (SINE), major satellites, and simple repeats²⁹. The biological significance of repetitive
244 element methylation/hydroxymethylation is unknown and has been difficult to explore in a cell
245 type-specific manner. Input and positive fractions from Aldh1l1-NuTRAP and Cx3cr1-NuTRAP
246 brain samples were analyzed for mCG, hmCG, and mCH content in whole genome, repeats, and
247 non-repeats (**Supplemental Figure 9 A-C**). In general, there were either no or minimal
248 differences in mCG levels evident in repeat elements (**Supplemental Figure 9D**). However,
249 hmCG and mCH repeat element (SINE, LINE, LTR, and simple repeat) levels were lower in the
250 Cx3cr1-NuTRAP INTACT positive fraction as compared to the other groups. These findings
251 identify epigenetic markers that are microglia- and repetitive element-specific.

252 **RNAseq analysis of microglial transcriptome 24 hours after LPS challenge in the Cx3cr1-** 253 **NuTRAP mouse brain.**

254 To probe the utility of using NuTRAP models to identify cell type-specific molecular changes not
255 observable in tissue level analyses, we performed an acute LPS administration paradigm in the

256 Cx3cr1-NuTRAP model. Systemic delivery of LPS is commonly used to study microglial
257 responses in the brain³⁰⁻³². Toll-like receptors (TLRs) are pattern recognition receptors expressed
258 by innate immune cells, such as microglia, and recognize and respond to conserved structural
259 motifs called pathogen-associated molecular patterns (PAMPs) including LPS, initiating a
260 cascade of molecular reactions resulting in the upregulation of pro-inflammatory cytokines and
261 chemokines³³.

262 To interrogate the microglial transcriptome and epigenome Cx3cr1-NuTRAP mice were
263 administered a single i.p. injection of 5 mg/kg LPS or PBS as sham control. To confirm induction
264 of inflammation by LPS, plasma and brain tissues were analyzed for content of inflammatory
265 cytokines. Circulating IL6, TNF, and IFN γ contents were elevated as early as at 4 hours post LPS
266 treatment and specifically IL-6 remained elevated in plasma and brain after 24 hours
267 **(Supplemental Figure 10 A-B)**. Brain sections were also immunostained with mCherry and
268 CD11b antibodies to visualize the specificity of cre-mediated recombination in microglial cells in
269 both treatment groups **(Supplemental Figure 10C)**. At 24 hours post LPS or PBS injection, brains
270 from Tam-induced Cx3cr1-NuTRAP mice were collected for TRAP and INTACT protocols.
271 Initially, TRAP-isolated RNA samples were processed for qPCR analysis of genes associated
272 with microglia and downstream activation of the TLR4 pathway in input, negative, and positive
273 fractions **(Supplemental Figure 11)**. Microglial markers were highly enriched in the positive
274 fraction of PBS- and LPS-treated mice compared to all input and negative fractions. Additionally,
275 induction of C1qa, Itgam, Myd88, Il1 α , Il1 β , and Tnfa were evident in LPS TRAP samples but
276 were not observable in input or negative fractions **(Supplemental Figure 11)**. In the design of the
277 RNAseq experiment, libraries were made from RNA from input and positive TRAP fractions,
278 excluding the negative fraction for further analyses. PCA revealed separation of samples by
279 fractionation in the first component (68.96 %), and separation of samples by treatment in the
280 second component (13.03%) **(Figure 8A)**. Differential gene expression in response to LPS was
281 compared between positive fraction and input. LPS-induced changes demonstrate higher fold
282 changes when microglial RNA is isolated by TRAP **(Figure 8B)** as also evident in heatmap
283 presentation with hierarchical clustering of gene expression that differentiated input and positive
284 fractions first and secondly by treatment **(Figure 8C)**. Collectively, the data suggest that the
285 NuTRAP approach produced excellent microglia-specific gene enrichment, microglial responses
286 to a stimulus, such as LPS, can be revealed, or are more pronounced when compared to analysis
287 of whole tissue.

288 Although a handful of studies have suggested DNA methylation as a principal regulator of
289 microglial activation³⁴, little microglia-specific *in vivo* evidence is available to compare DNA
290 methylation with concurrent changes in transcriptomic response. By coupling LPS administration
291 with the cell type-specific Cx3cr1-NuTRAP model we are able to interrogate dynamic changes in
292 DNA methylation in Cx3cr1⁺ (microglia) cells with their paired transcriptomic changes indicative
293 of a pro-inflammatory response. Cx3cr1-NuTRAP mice were systemically administered 5 mg/kg
294 LPS or PBS by ip injection and 24 hours after treatment and in parallel with the TRAP procedure,
295 half brains were dissected for INTACT protocol and downstream applications. BSAS analysis of
296 selected microglial (Gpr84, Aif1), astrocytic (Fabp7), and neuronal (Eno2) marker genes was
297 conducted on input and INTACT-isolated positive fractions. The INTACT-isolated positive fraction
298 exhibited lower CG methylation (mCG) in the promoter region of microglial marker genes Gpr84
299 and Aif1 as compared to input, regardless of treatment (**Supplemental Figure 12 A, C**).
300 Hypomethylation of the Gpr84 and Aif1 promoters in the positive fraction correlated with their
301 respective increased gene expression by TRAP-RNAseq (**Supplemental Figure 12 B, D**). There
302 was no correlation between gene expression and methylation for the astrocytic marker Fabp7 or
303 the neuronal marker Eno2 (**Supplemental Figure 12 E-H**).

304 As the resident macrophages of the CNS, microglia are equipped with a number of TLRs,
305 including TLR2 and TLR4. TLRs 2 and 4 recognize LPS as a PAMP and initiate an inflammatory
306 cascade that acts through downstream mediators, like Myd88 and Ly96. To assess the effects
307 of LPS administration on DNA methylation, BSAS of inflammatory genes (Tlr2, Myd88, Ly96) was
308 conducted on INTACT-isolated DNA in parallel with TRAP-RNAseq. Upon LPS administration,
309 the Tlr2 promoter was hypomethylated in the positive fraction but not input, when compared to
310 their respective vehicle controls (**Figure 8D**). Hypomethylation of the Tlr2 promoter in the positive
311 fraction with LPS correlated with increased gene expression in the positive fraction with LPS
312 (**Figure 8D**). Myd88, a downstream effector of TLRs, showed decreased CG methylation in the
313 positive fraction with LPS treatment when compared to PBS control, while the input had no change
314 in Myd88 methylation with LPS treatment (**Figure 8E**). The change in promoter mCG in the
315 positive fraction with LPS was correlated to an increase in Myd88 gene expression (**Figure 8E**).
316 While the positive fraction showed a decrease in Ly96 methylation with LPS administration
317 (**Figure 8F**), there was no change in Ly96 gene expression (**Figure 8F**). Of note, in the cases of
318 Tlr2, Myd88, and Ly96 promoter methylation, the changes in methylation observed in the positive
319 fraction were not apparent in the input. This highlights the importance of studying DNA
320 modifications in a cell type-specific manner and the value of the Cx3cr1-NuTRAP model to study
321 the relationship between microglia genomic methylation and transcriptome.

322 Lastly, to further demonstrate the utility of the NuTRAP system for additional molecular analyses,
323 we examined microglial proliferation by stable isotopic labeling. This approach uses deuterium
324 oxide (D₂O) in drinking water, which quickly equilibrates its labeling with the deoxyribose moiety³⁵.
325 The labeled deoxyribose moiety is then incorporated into DNA through de novo synthesis only,
326 with no contribution of salvage pathways or repair processes. After 30 days of D₂O administration
327 to Cx3cr1-NuTRAP mice INTACT isolation was performed and the DNA extracted. Incorporation
328 of deuterium was determined through GC-MS in the positive fraction and input and found to be
329 significantly greater in the positive fraction (**Supplemental Figure 13**) indicating that microglial
330 replication is greater than the average of all CNS cellular populations³⁶.

331 In summary, the results offer extensive evidence to support the combination of inducible cre/lox
332 and NuTRAP models as a suitable and powerful approach for the parallel study of the cell-specific
333 epigenetic and transcriptomic signatures in the brain.

334 Discussion

335 Two of the main challenges that obstruct the interpretation of neuroepigenetic studies are the
336 isolation of specific cell types from the complex milieu of the CNS and the lack of approaches to
337 analyze both the transcriptome and epigenome of such cells. Combining TRAP and INTACT
338 tagging into one construct that can be temporally controlled provides a tractable approach for cell
339 type-specific paired analysis of the epigenome and transcriptome. We present the development,
340 validation and application of this approach for astrocytes and microglia. These approaches could
341 be applied to any CNS cell type for which there is an appropriate cre driver line. The inducible
342 nature of the Cre-Lox systems used (Aldh111-cre/ERT2¹² and Cx3cr1-cre/ERT2¹³), in combination
343 with the recently developed NuTRAP construct¹¹, also allows for temporal control of labeling of
344 cell-specific nuclei and polyribosomes, avoiding the deleterious effects of constitutive DNA
345 recombination during development and potential confounds from having developmental
346 expression of the cre when studying adult/aged stages of the lifespan. To the best of our
347 knowledge, this is the first study applying the NuTRAP model to neuroscience research, or using
348 Tam-dependent induction. Importantly, these results also provide approaches for generation and
349 validation of NuTRAP neuroscience models crossed to any relevant cell type-specific cre line.

350 The NuTRAP system combining TRAP and INTACT tagging approaches into one floxed construct
351 was first described and applied to adipocytes¹¹. The potential use in neuroscience research is
352 relatively obvious as a number of reports describe the limitations of using cell sorting through
353 surface markers. Importantly for glial research the very act of flow cytometry may change the
354 activational state of these cells⁵. TRAP and INTACT isolations allow nucleic acids to be rapidly
355 isolated from subcellular fractions decreasing the likelihood of isolation artifacts.

356 Validation of inducible cell type-specific NuTRAP models requires multiple steps to confirm the
357 specificity of both the NuTRAP induction and the TRAP and INTACT isolations. The flow
358 cytometry and imaging validation experiments demonstrated Tam-dependent cell type-specific
359 induction of the NuTRAP construct in astrocytes and microglia. Transcriptomic studies
360 demonstrated TRAP isolation of highly enriched astroglial RNA in the Aldh111-NuTRAP and
361 microglial RNA in the Cx3cr1-NuTRAP positive fractions isolated by TRAP procedures. Validation
362 of cell type-specific DNA poses a more challenging question but cell-type specific DNA
363 modification patterns are consistent with the concept of cell type-specific hypomethylation of cell
364 marker genes. Together these studies provide high confidence that these are valid models to be
365 applied in a broad spectrum of neuroscience research studies ranging from brain aging, to
366 neurodegenerative and neuropsychiatric studies. Moreover, the validation approach can be

367 applied to any new NuTRAP model and the protocols described here can be scaled-down to
368 microdissected CNS tissue, such as a single hippocampus or retina sample (not shown).

369 These findings also reveal new insights into astrocyte and microglia biology. Non-neuronal cells
370 have been reported to have less CG hydroxymethylation than other cells in the brain and also
371 have lower non-CpG methylation¹. While it is sometimes simplistically believed
372 hydroxymethylation and non-CpG methylation are restricted to neurons these findings provide
373 evidence that while CG hydroxymethylation and non-CG methylation levels may be lower in non-
374 neuronal cell populations yet they are not absent. To date, there is no explanation for why
375 hydroxymethylation is not evident in the non-CG context but as previously reported this
376 modification is absent or at a level below detection^{14,25}.

377 To determine the sensitivity of cre/ERT2-NuTRAP approaches for the detection of molecular
378 changes at the cell type-specific level that are not evident in tissue homogenates we acutely
379 administered LPS to Cx3cr1-NuTRAP mice. Microglia-specific transcriptome and epigenome
380 changes were revealed that could not be detected without affinity purification. Further, we
381 demonstrated how our approach in combination with other labeling approaches, in this case D₂O,
382 could help provide insight into how cell-specific genomic changes influence dynamic processes
383 of the cell, such as replication. Collectively, our experiments demonstrated that the NuTRAP
384 approach can be applied to CNS cell populations and INTACT approaches can be used to study
385 DNA modifications, not only at the whole genome and gene promoter levels, but also in repeat
386 elements of the genome, as shown here for the first time.

387 In light of the increasing interest in cell-specific contributions to the CNS epigenome^{2,24} and
388 transcriptome^{3,5,12,19,20,30,31,37} landscapes, the use of transgenic inducible cre mouse models that
389 allow for manipulation of specific floxed genes, or tagging of cell-specific nuclei/and or polysomes
390 represent valuable research tools. Models using constructs such as INTACT², TRAP⁸, and
391 RiboTag⁹, constitute critical advancements for DNA or RNA studies of specific cell types.
392 However, the introduction of inducible-cre mouse lines in combination with NuTRAP technology,
393 as validated in this study, is a powerful strategy in the interrogation of the cell type-specific
394 dependent differences in the transcriptomes and epigenomes in the adult CNS.

395 **Acknowledgements**

396 The authors acknowledge the Laboratory for Molecular Biology and Cytometry Research
397 at OUHSC for the use of the Core Facility, which provided flow cytometry services, the Cellular
398 Imaging Core, at the Dean McGee Institute, OUHSC, for providing access to vibratome and
399 confocal imaging equipment, and the Oklahoma Medical Research Foundation Clinical Genomics
400 Center, which provided sequencing services. Computing for this project was performed at the OU
401 Supercomputing Center for Education & Research (OSCER) at the University of Oklahoma (OU).
402 The authors also acknowledge Adeline Machalinski (mouse colony management and
403 genotyping), Robyn Berent (administrative support and lab management), P. Marlow for figure
404 preparation, and Dr. Michael H. Elliott for critical scientific discussions during the preparation of
405 this manuscript.

406 This work was supported by grants from the National Institutes of Health (NIH)
407 P30AG050911, R56AG059430, R01AG059430, P20GM125528, T32AG052363, F31AG064861,
408 P30EY021725, R01AG052606, Oklahoma Center for Adult Stem Cell Research (OCASCR), a
409 program of the Oklahoma Tobacco Settlement Endowment Trust, and Presbyterian Health
410 Foundation. This work was also supported in part by the MERIT award I01BX003906 from the
411 United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and
412 Development Service.

413 **Methods**

414 **Animals**

415 All animal procedures were approved by the Institutional Animal Care and Use Committee at the
416 University of Oklahoma Health Sciences Center (OUHSC). Mice were purchased from the
417 Jackson Laboratory (Bar Harbor, ME), bred, and housed in the animal facility at the OUHSC,
418 under SPF conditions in a HEPA barrier environment. In separate breeding strategies Aldh111-
419 Cre/ERT2^{+/wt} males (stock number # 29655)¹² and Cx3cr1-Cre/ERT2^{+/+} males (stock # 20940)¹³
420 were mated with NuTRAP^{flox/flox} females (stock # 029899)¹¹ to generate the desired progeny,
421 Aldh111-cre/ERT2^{+/wt}; NuTRAP^{flox/wt} (Aldh111-cre/ERT2⁺; NuTRAP⁺) and Cx3cr1-cre/ERT2^{+/wt};
422 NuTRAP^{flox/wt} (Cx3cr1-cre/ERT2⁺; NuTRAP⁺). The cross of the Vav-iCre mouse model (stock #
423 008610)³⁸ with the NuTRAP^{flox/flox} line did not show the specific labeling of brain microglia in
424 agreement with a previous report³, and was not used for further validations. DNA was extracted
425 from mouse ear punch samples for genotyping. Mice (males and females) were ~3 months old at
426 the time of performing experiments. Euthanasia prior to tissue harvesting was carried out either
427 by cervical dislocation, or by cardiac perfusion with phosphate buffered saline (PBS), upon deeply
428 anesthetizing mice with ketamine/xylazine. The primers used for genotyping (Integrated DNA
429 Technologies, Coralville, IA) are included in **Supplemental table 1**.

430 **Tamoxifen (Tam) treatment**

431 At ~3 months of age, mice received a daily intraperitoneal (ip) injection of tamoxifen (Tam)
432 solubilized in 100% sunflower seed oil by sonication (100 mg/kg body weight, 20 mg/ml stock
433 solution, #T5648; Millipore Sigma, St. Louis, MO) for five consecutive days^{12,14}.

434 **Lipopolysaccharide (LPS) treatment, protein sample preparation, and suspension array**

435 At 3-4 weeks post-Tam treatment, Cx3cr1-cre/ERT2⁺; NuTRAP⁺ mice were systemically
436 administered 5 mg/kg LPS³¹ (#L2262, 1 mg/ml stock solution; Millipore Sigma) or vehicle (PBS)
437 by ip injection. Blood was collected from the facial vein of mice at 4h and 24h post-LPS treatment,
438 using a 5-mm sterile Goldenrod animal lancet (MEDpoint, Mineola, NY), mixed with 5µl 0.5M
439 EDTA to prevent coagulation³⁹, and centrifuged at 1,000 x g for 10 min for plasma collection. At
440 24h post LPS treatment, mice were euthanized and a sagittal slice circumscribing the medial line
441 of their brains was harvested and homogenized in RIPA buffer supplemented with 1X HaltTM
442 protease inhibitor cocktail (#78437; ThermoFisher Scientific, Grand Island, NY) by sonication. The
443 supernatants from tissue homogenates were assayed for protein content using a BCA protein

444 method (#23225; ThermoFisher Scientific) and along with diluted plasma samples, used for
445 protein analyses. Suspension array analyte concentrations were determined using a Bio-Rad Bio-
446 Plex System Luminex 100 and Bio-Plex manager 5.0 (Bio-Rad Laboratories, Hercules, CA)⁴⁰.
447 Milliplex Map luminex-based assays were used to quantify the mouse inflammatory cytokines IL-
448 6, TNF α , and INF γ (#MICYTOMAG-70K; EMD Millipore, Billerica, MA). The concentration of each
449 analyte detected in plasma was expressed as log transformed (pg analyte/ml) and that detected
450 in tissue homogenate as pg analyte/mg protein.

451 **Flow cytometry**

452 Halves of mouse brains were rinsed in D-PBS, sliced into 8-12 sagittal sections and placed into
453 gentleMacs C-tubes, and processed for generation of single- cell suspensions using the Adult
454 brain dissociation kit and gentleMacsTM Octodissociator system (#130-107-677 and #130-095-
455 937, respectively, Milteny Biotech, San Diego, CA). The single-cell suspensions were then
456 immunostained for flow cytometric analysis of EGFP⁺ cell populations in the brain. The gating
457 strategy of single cells was set to EGFP⁺/ACSA2⁺ for astrocytes (**Supplemental Figure 14**) and
458 EGFP⁺/CD11b⁺ for microglia (**Supplemental Figure 15**). A 488 nm (blue) laser with 530/30 and
459 580/30 filter combinations was used to gate on EGFP⁺ cells within single cells (singlets) without
460 auto-fluorescence interference. Subsequent gating based on CD11b or ACSA-2 expression was
461 done with 640 nm laser and 676/629 filter, or with 488 nm laser and 740 LP filter combinations,
462 respectively. The antibodies used were anti-mouse CD11b: APC (#17-0112, clone M1/70)
463 (eBioscience, San Diego, CA), and ACSA-2: PE-Vio770 (#130-116-246, Milteny Biotec)¹⁵.
464 Isotype controls for each antibody and unstained cells were used for proper post-color
465 compensation (**Supplemental Figures 14-15**). Samples were analyzed using a Stratadigm
466 S1400Exi flow cytometer platform (Stratadigm, San Jose, CA) and CellCapTure v5.0 RC12 and
467 v4.1 RC10 software (Stratadigm) at the Laboratory for Molecular Biology and Cytometry Research
468 core facility at OUHSC.

469 **Immunocytochemistry and imaging**

470 For immunohistochemistry (IHC), mouse brains were harvested and hemisected. Samples were
471 fixed for a duration of 4h in 4% paraformaldehyde, embedded in 2% agarose, and vibratome-
472 sectioned (Vibratome 3000 Sectioning System, The Vibratome Company, St. Louis, MO), as
473 previously described⁴¹. Two-hundred μ m-thick sections were permeated for 2h in PBS containing
474 3% BSA and 0.2% Triton, and processed for fluorescence immunostaining. The primary
475 antibodies included rabbit anti-mCherry (#ab167453, 1:500, Abcam, Cambridge, MA), chicken

476 anti-GFAP (#ab4674, 1:1,000, Abcam), rabbit anti-NeuN (#ab177487, 1:200, Abcam), and rat
477 anti-CD11b (#C227, 1:200, Leinco Technologies, St. Louis, MO). For confocal imaging of nuclei
478 suspensions, unfixed, freshly isolated nuclei were mixed with DAPI solution. Sequential imaging
479 of brain samples and freshly isolated nuclei was performed on an Olympus FluoView confocal
480 laser-scanning microscope (FV1200; Olympus; Center Valley, PA) at the Dean McGee Eye
481 Institute imaging core facility at OUHSC. Microscope and FLUOVIEW FV1000 Ver. 1.2.6.0
482 software (Olympus) settings were identical/similar for samples within experiments at same
483 magnification. The experimental format files were .oif (4-channel capture) or .oib (2 or 3-channel
484 capture). For brain samples, the final Z-stack generated was achieved at 1.14-1.26 μm step size
485 with a total of 12-16 optical slices at 20X magnification (1X, 1.5X or 2X zoom) and/or 0.55-0.62
486 μm step size with a total of 23-26 optical slices at 40 X magnifications (1.5X zoom). For nuclei
487 samples, the Z-stack was achieved at 1.16 μm step size with 6-8 optical slices at 20X
488 magnification (2X zoom). Instrument settings for capture of raw images, as well as downstream
489 processing (Adobe Photoshop CS5.1) of each raw image used for figure assembly are disclosed
490 under the **Supplemental table 7**: equipment and settings.

491 **Isolation of Nuclei from Tagged specific nuclei (INTACT) and gDNA extraction**

492 The purification of viable, cell-specific nuclei from brain tissue from Tam-induced Aldh11l1-
493 cre/ERT2⁺; NuTRAP⁺ and Cx3cr1-cre/ERT2⁺; NuTRAP⁺ mice was achieved by combining two
494 previously published protocols, with modifications^{10,42}. For each mouse, a hemisected half-brain
495 was rinsed in ice-cold 1X PBS, minced into small pieces and homogenized in 4 ml ice-cold nuclei
496 EZ lysis buffer (#NUC-101, Millipore Sigma) supplemented with 1X HaltTM protease inhibitor
497 cocktail (ThermoFisher Scientific) using a glass dounce tissue grinder set (#D9063; Millipore
498 Sigma: 20 times with pestle A and 20 times with pestle B)⁴². Undissociated tissue, largely
499 composed of blood vessels, was removed by centrifugation at 200 x g for 1.5 min at 4°C⁴³, and
500 the supernatant containing the nuclear material filtered through a 30 μm strainer and centrifuged
501 at 500 x g for 5 min at 4°C. The resulting nuclear pellet was resuspended in nuclei lysis EZ buffer,
502 incubated on ice for 5 min, washed by centrifugation, and resuspended in 300 μl nuclei EZ storage
503 buffer by gentle trituration with a micropipette. From the total resuspended pellet volume, 10%
504 was reserved as input nuclei fraction and the rest was diluted with 1.6 ml nuclei purification buffer
505 (NPB: 20 mM HEPES, 40 mM NaCl, 90 mM KCl, 2 mM EDTA, 0.5 mM EGTA, 1X HaltTM protease
506 inhibitor cocktail), and subjected to the INTACT protocol¹⁰. Briefly, 30 μl of resuspended M-280
507 Streptavidin Dynabeads (#11205, ThermoFisher Scientific) were added into a fresh 2 ml
508 microcentrifuge tube and washed with 1ml of NPB using a DynaMag-2 magnet (#12321;

509 ThermoFisher Scientific) for a total of three washes (1 min incubation/each). The washed beads
510 were reconstituted to their initial volume (30 μ l) with NPB and gently mixed with the nuclear
511 suspension. The mixture of nuclei and magnetic beads was incubated at 4°C for 40 min under
512 gentle rotation settings to allow the affinity binding of streptavidin beads to the cell-specific,
513 biotinylated nuclei. After incubation, the streptavidin-bound nuclei were magnetically separated
514 with the DynaMag-2 magnet for a period of 3 min and the unbound nuclei collected in a fresh 2
515 ml microcentrifuge tube, centrifuged at 4°C (1,000 x g, 3 min), resuspended in 100 μ l of NPB and
516 reserved as the negative nuclei fraction. The nuclei bound to the beads were washed in the
517 magnet for three washes (1 min/each), resuspended in 30 μ l of NPB, and reserved as the positive
518 nuclei fraction. From each nuclear fraction (input, negative, and positive), a 3 μ l aliquot was mixed
519 with equal volume of DAPI counterstain and used for confocal microscopy visualization and
520 calculation of purity percentage (3-5 fields of view per sample). The AllPrep DNA/RNA kit Micro
521 (#80284, Qiagen, Germantown, MD) was used to extract gDNA from each sample¹⁰. gDNA was
522 quantified with a Nanodrop 2000c spectrophotometer (Thermofisher Scientific) and its quality
523 assessed by genomic DNA D1000 (#5067-5582) with a 2200 TapeStation analyzer (Agilent
524 Technologies, Santa Clara, CA).

525 **Bisulfite amplicon sequencing (BSAS)**

526 INTACT-isolated gDNA samples (input, negative fraction, and positive fraction) and mouse
527 methylation controls (#80-8063-MGHM-5 and #80-8064-MGUM-5; EpigenDX, Hopkinton, MA)
528 were diluted in nuclease free elution buffer (Qiagen) to a 10 ng/ μ l concentration (200 ng gDNA in
529 20 μ l final volume). DNA was bisulfite converted for methylation analysis with the EZ DNA
530 Methylation-Lightning™ Kit (#D5030T; Zymo Research, Irvine, CA), according to the
531 manufacturer's guidelines. For methylation quantitation of gene promoters, primer sets
532 (Integrated DNA Technologies; **Supplemental Table 2**) were designed based on the appropriate
533 National Center for Biotechnology Information (NCBI) reference genome using the Methyl Primer
534 Express v1.0 software (Thermofisher Scientific) to amplify 250-350 bp regions of interest
535 upstream or downstream the transcription start site (TSS) from bisulfite converted DNA, as
536 previously described⁴⁴. Bisulfite specific PCR optimization protocols were run to amplify and
537 visualize amplicons by HSD1000 TapeStation. PCR amplicons were cleaned with Agencourt
538 AmpureXP beads (#A63882; Beckman Coulter Life Sciences, Indianapolis, IN) using a two-sided
539 size selection with 0.7X bead ratio followed by 0.15X bead ratio. Following clean-up, the
540 amplicons were quantified using Qubit™ dsDNA HS assay kit (#Q32851; Thermofisher Scientific)
541 and 5 ng of each amplicon was pooled per sample. One ng of the pooled amplicons was used for

542 library construction with the Nextera XT DNA library preparation kit (#FC-131-1096; Illumina, San
543 Diego, CA), according to the manufacturer's guidelines. Libraries were quantified with Qubit™
544 dsDNA HS assay kit and TapeStation HD1000, normalized to 1 nM or 4 nM, and pooled for
545 sequencing. Pooled libraries were then sequenced on iSeq or MiSeq (Illumina) at loading
546 concentrations 35 pM or 8 pM, respectively. Fastq files were aligned to amplicon sequences in
547 CLC Genomics Workbench 11.0 (Qiagen) using the "Map Bisulfite Reads to Reference" feature.
548 Site-specific CpG (CG) and CH methylation percentages were extracted for downstream analysis.

549 **Library construction and oxidative bisulfite sequencing (OxBS-seq)**

550 Protocols were carried out as previously described¹⁴. For each input, negative, and positive
551 INTACT-isolated sample 400 ng of gDNA was brought up to 50 µl volume with 1X low-EDTA TE
552 buffer and sheared with a Covaris E220 sonicator (Covaris, Inc., Woburn, MA) to an average 200
553 base pair size using the following settings: intensity of 5, duty cycle of 10%, 200 cycles per burst,
554 2 cycles of 60 seconds, at 7 °C. The size of sheared products was confirmed by capillary
555 electrophoresis (DNA D1000, Agilent). gDNA fragments were cleaned by an Agencourt bead-
556 based purification protocol, after which gDNA was quantified (Qubit™ dsDNA, Thermofisher
557 Scientific). Two aliquots of 200 ng gDNA fragments were prepared in a 12 µl volume to which 1 µl
558 of spike-in control DNA (0.08 ng/ul) with known levels of specific mC, hmC, and fC at individual
559 sites was added. End repair, ligation of methylated adaptors (#L2V11DR-BC 1-96 adaptor plate,
560 NuGEN, Tecan Genomics, Inc., Redwood City, CA) and final repair were performed according to
561 manufacturer's instructions (Ovation Ultralow Methyl-Seq Library System, NuGEN). Of the two
562 DNA aliquots per sample, one was oxidized and then bisulfite- converted and the other only
563 bisulfite-converted with the True Methyl oxBS module (NuGEN) with desulfonation and
564 purification. 22 µl of libraries were eluted from the magnetic beads. qPCR was used to determine
565 the number (N) of PCR cycles required for library amplification. Bisulfite-converted samples were
566 amplified for 7 cycles while oxidative bisulfite- converted samples were amplified for 11 cycles
567 [95° C- 2 min, N (95°C-15 s, 60°C-1 min, 72° C-30s)]. Amplified libraries were purified with
568 Agencourt beads and eluted in low-EDTA TE buffer. TapeStation HD1000 was used to validate
569 and quantify libraries. Amplified libraries were normalized to a concentration of 4 nM and pooled,
570 denatured, and diluted to 12 pM for sequencing on the NovaSeq 6000 (Illumina) according to
571 manufacturer's guidelines with the exception of a custom sequencing primer (MetSeq Primer) that
572 was spiked in with the Illumina Read 1 primer to a final concentration of 0.5 µM.

573 **OxBS-seq data analysis**

574 Global levels of mCG, hmCG, and mCH were analyzed as previously described.¹⁴ Prior to
575 alignment, paired-end reads were adaptor-trimmed and filtered using Trimmomatic⁴⁵ 0.35. End-
576 trimming removed leading and trailing bases with Q-score<25, cropped 4 bases from the start of
577 the read, dropped reads less than 25 bases long, and dropped reads with average Q-score<25
578 Alignment of trimmed bisulfite converted sequences was carried out using Bismark⁴⁶ 0.16.3 with
579 Bowtie 2⁴⁷ against the mouse reference genome (GRCm38/mm10). Bam files were de-duplicated
580 using Bismark. Methylation call percentages for each CpG and non-CpG (CH) site within the
581 genome were calculated by dividing the methylated counts over the total counts for that site in
582 the oxidative bisulfite - converted libraries (OXBS). Genome-wide CpG and CH methylation levels
583 were calculated separately. Hydroxymethylation levels in CpG (hmCG) and CH (hmCH) contexts
584 were calculated by subtracting call levels from the oxidative bisulfite-converted (OXBS) libraries
585 from the bisulfite-converted (BS) libraries. BAM files generated by MethylSeq (Basespace,
586 Illumina) were run through MethylKit in R⁴⁸ to generate context-specific (CpG/CH) coverage text
587 files. Bisulfite conversion efficiency for C, mC, and hmC was estimated using CEGX spike-in
588 control sequences. Untrimmed fastq files were run through CEGX QC v0.2, which output a
589 fastqc_data.txt file containing the conversion mean for C, mC, and hmC. Analysis of methylation
590 levels in the proximity of the promoter region was performed on a list of selected genes as follows.
591 The R package Enriched Heatmap⁴⁹ was used to intersect methylation call files with genomic
592 coordinates of gene lists. Flanking regions of 4000 nucleotides were constructed upstream of the
593 transcription start site (TSS) and downstream of the transcription end site (TES) and then split
594 into 20 bins of 200 nucleotides each. The gene body was split into 27 equal bins, depending on
595 the gene length. The average of each bin for all genes in the list was then plotted versus the bin
596 number to give a visualization of the overall pattern of mCG within and around the genes
597 contained in the gene lists. Average mCG and hmCG levels were calculated for the upstream
598 region (-4kb to TSS), gene body (TSS to TES), and downstream region (TES to +4kb) for each
599 gene list and biological replicate, and subjected to 2-way ANOVA statistical analysis with Sidak's
600 multiple comparisons correction (GEO repository under accession code GSE140271).

601 Repeat element mCG, mCH, and hmCG was also examined. Repeat masker bed files were
602 extracted from the UCSC Genome Browser Table Browser⁵⁰. The context-specific CpG/CH
603 MethylKit text files were intersected with the repeat masker bed files using 'bedtools', and percent
604 methylation was calculated by dividing the average percent methylation at all common sites by

605 the total number of sites. This was done for long interspersed nuclear elements (LINE), short
606 interspersed nuclear elements (SINE), long terminal repeats (LTR), and simple repeats.

607 **Translating Ribosome Affinity Purification (TRAP) and RNA extraction**

608 The purification of cell-specific RNA from brain tissue from Tam-induced *Aldh111-cre/ERT2⁺*;
609 *NuTRAP⁺* and *Cx3cr1-cre/ERT2⁺*; *NuTRAP⁺* mice was achieved by following an established
610 protocol, with slight modifications^{11,51,52}. For each mouse, a hemisected half-brain was minced
611 into small pieces and homogenized in 2 ml ice-cold homogenization buffer (50 mM Tris, pH 7.4;
612 12 mM MgCl₂; 100 mM KCl; 1% NP-40; 1 mg/ml sodium heparin; 1 mM DTT) supplemented with
613 100 µg/ml cycloheximide (#C4859-1ML, Millipore Sigma), 200 units/ml RNaseOUT™
614 Recombinant Ribonuclease Inhibitor (#10777019; Thermofisher), and 1X cOmplete™, EDTA-free
615 Protease Inhibitor Cocktail (#11836170001; Millipore Sigma) with a glass dounce tissue grinder
616 set (#D8938; 10 times with pestle A and 10 times with pestle B). Homogenate was transferred to
617 a 2 mL round-bottom tube and centrifuged at 12,000 x g for 10 minutes at 4°C. After centrifugation,
618 100 µL of the supernatant was saved as input. The remaining supernatant was transferred to a 2
619 mL round-bottom tube and incubated with 5 µg/µl of anti-GFP antibody (ab290; Abcam) at 4°C
620 with end-over-end rotation for one hour. Dynabeads™ Protein G for Immunoprecipitation
621 (#10003D; Thermofisher) were washed three times in 1 ml ice-cold low-salt wash buffer (50mM
622 Tris, pH 7.5; 12mM MgCl₂; 100mM KCl; 1% NP-40; 100µg/ml cycloheximide; 1mM DTT). After
623 removal of the last wash, the homogenate/antibody mixture was transferred to the 2 ml round-
624 bottom tube containing the washed Protein-G Dynabeads and incubated at 4°C with end-over-
625 end rotation for an additional two hours. Magnetic beads were collected using a DynaMag-2
626 magnet and the unbound- ribosomes and associated RNA saved as the “negative” fraction. Beads
627 were then washed three times with 1 ml of high-salt wash buffer (50mM Tris, pH 7.5; 12mM
628 MgCl₂; 300mM KCl; 1% NP-40; 100µg/ml cycloheximide; 2mM DTT). Following the last wash,
629 350 µL of Buffer RLT (Qiagen) supplemented with 3.5 µl 2-β mercaptoethanol was added directly
630 to the beads and incubated with mixing on a ThermoMixer (Eppendorf) for 10 minutes at room
631 temperature. The beads were magnetically separated and the supernatant containing the target
632 bead-bound ribosomes and associated RNA was transferred to a new tube. 350 µl of 100%
633 ethanol was added to the tube (“positive” fraction) and then loaded onto an RNeasy MinElute
634 column. RNA was isolated using RNeasy Mini Kit (#74104, Qiagen), according to manufacturer’s
635 instructions. RNA was quantified with a Nanodrop 2000c spectrophotometer (Thermofisher
636 Scientific) and its quality assessed by HSRNA screentape with a 2200 Tapestation analyzer
637 (Agilent Technologies).

638 **Library construction and RNA sequencing (RNA-seq)**

639 The NEBNext Ultra II Directional Library Prep Kit for Illumina (#NEBE7760L; New England Biolabs
640 Inc., Ipswich, MA) was used on 25 ng of total RNA for the preparation of strand-specific
641 sequencing libraries from each TRAP-isolated RNA sample (input, negative fraction, and positive
642 fraction) and from conventionally isolated RNA samples from brain (tissue), according to
643 manufacturer's instructions. Briefly, polyA containing mRNA was purified using oligo-dT attached
644 magnetic beads. mRNA was chemically fragmented and cDNA synthesized. For strand-
645 specificity, the incorporation of dUTP instead of dTTP in the second strand cDNA synthesis does
646 not allow amplification past this dUTP with the polymerase. Following cDNA synthesis, each
647 product underwent end repair process, the addition of a single 'A' base, and finally ligation of
648 adapters. The cDNA products were further purified and enriched using PCR to make the final
649 library for sequencing. Library sizing was performed with HS RNA ScreenTape (#5067-5579;
650 Agilent Technologies) and libraries were quantified by qPCR (Kappa Biosystems, Inc.,
651 Wilmington, MA). The libraries for each sample were pooled at 4 nM concentration and
652 sequenced using an Illumina NovaSeq 6000 system (SP PE50bp) at the Oklahoma Medical
653 Research Foundation Genomics Facility.

654 **RNA-Seq Data Analysis**

655 Following sequencing, reads were trimmed, aligned, differential expression statistics and
656 correlation analyses were performed in Strand NGS software package (Agilent), as previously
657 described¹⁴. Reads were aligned against the Mm10 build of the mouse genome (2014.11.26).
658 Alignment and filtering criteria included: adapter trimming, fixed 2bp trim from 5' and 6bp from 3'
659 ends, a maximum number of one novel splice allowed per read, a minimum of 90% identity with
660 the reference sequence, a maximum of 5% gap, trimming of 3' end with Q<30. Alignment was
661 performed directionally with Read 1 aligned in reverse and Read 2 in forward orientation. Reads
662 were filtered based on the mapping status and only those reads that aligned normally (in the
663 appropriate direction) were retained. Normalization was performed with the DESeq algorithm⁵³.
664 Transcripts with an average read count value >20 in at least 100% of the samples in at least one
665 group were considered expressed at a level sufficient for quantitation per tissue and those
666 transcripts below this level were considered not detected/not expressed and excluded, as these
667 low levels of reads are close to background and are highly variable. For statistical analysis of
668 differential expression, a one-way ANOVA or two-way ANOVA with the factors of TRAP fraction
669 and treatment and a Benjamini-Hochberg Multiple Testing Correction followed by Student-
670 Newman Keuls post hoc test were used. For those transcripts meeting this statistical criterion, a

671 fold change $>|1.25|$ cutoff was used to eliminate those genes which were statistically significant
672 but unlikely to be biologically significant and orthogonally confirmable due to their very small
673 magnitude of change. Visualizations of hierarchical clustering and principle components analysis
674 were performed in Strand Next Generation Analysis Software (NGS) (Version 3.1, Bangalore,
675 India). The entirety of the sequencing data is available for download in FASTQ format from NCBI
676 Sequence Read Archive (GSE140895 and GSE140974). Cell type specific marker gene lists were
677 generated from the re-analysis published by McKenzie et al.¹⁸ of immunopurified⁵⁴ and high
678 throughput single cell data from mice^{55,56}. Published lists were filtered first by mean enrichment
679 score of ≥ 3.5 and secondly to remove any genes that appeared on lists for multiple cell types.
680 Comparisons of astrocyte gene enrichment in this study to previously published Aldh1l1-
681 RiboTag¹² and Gfap-TRAP¹⁹ were performed by downloading raw fastq files with GEO accession
682 numbers GSE84540 and GSE99791, respectively, and processing the files through StrandNGS
683 as above, with minor alterations as necessitated by the type of sequencing data. After alignment,
684 astrocyte markers were classified by differential expression between the input and positive
685 fractions of Aldh1l1-RiboTag, Aldh1l1-TRAP, and Aldh1l1-NuTRAP was assessed by T-test,
686 BHMTCC <0.05 and FC >5 . The intersection of these gene lists was then used to construct a
687 ribosomal-tagging astrocyte gene list. In a similar manner, microglial marker genes identified in
688 this study (t-test, BHMTCC $p<0.05$ and FC(pos/input) >5) were compared to Cx3cr1(Jung)-
689 RiboTag⁵ and Cx3cr1(Litt)-TRAP³ by downloading raw fastq files with GEO accession numbers
690 GSE114001 and GSE108356, respectively, and processing as above. Gene expressions of
691 selected genes from previously published gene lists^{12,19,20} were imported into the IPA software
692 Ingenuity Pathway Analysis (IPA) 01.12 (Qiagen Bioinformatics) to assess pathway/biological
693 function enrichment analysis.

694 **Quantitative PCR (qPCR)**

695 Confirmation of gene expression levels was performed with qPCR as previously described^{14,57,58}.
696 cDNA was synthesized with the ABI High-Capacity cDNA Reverse Transcription Kit (Applied
697 Biosystems Inc., Foster City, CA) from 25ng of purified RNA. qPCR was performed with gene-
698 specific primer probe fluorogenic exonuclease assays (TaqMan, Life Technologies, Waltham,
699 MA, **Supplemental table 3**) and the QuantStudio™ 12K Flex Real-Time PCR System (Applied
700 Biosystems). Relative gene expression (RQ) was calculated with Expression Suite v 1.0.3
701 software using the $2^{-\Delta\Delta Ct}$ analysis method with GAPDH as an endogenous control.

702 **Stable Isotope Labeling**

703 Microglial proliferation was measured as incorporation of deuterium into purine deoxyribose as
704 previously described⁵⁹. Briefly, mice were given an intraperitoneal injection of 99.9% D₂O and
705 subsequently provided drinking water enriched with 8% D₂O for 30 days. Following INTACT
706 isolation, DNA was extracted from nuclei using QiAamp DNA mini kit (Qiagen, Valencia, CA)
707 according to manufacturer protocol. Extracted DNA was hydrolyzed overnight at 37 °C with
708 nuclease S1 and potato acid phosphatase. Hydrolysates were prepared for analysis of the
709 pentafluorobenzyl-*N,N*-di(pentafluorobenzyl) derivative of deoxyribose by GC-MS. Enrichment
710 of deuterium in DNA from bone marrow was similarly analyzed for each animal to determine
711 precursor enrichment. Fraction of new DNA was calculated based on the product/precursor
712 relationship.

713 **Data availability**

714 Sequencing data that support the findings of this study have been deposited in GEO repository
715 with the GSE140271 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140271>)
716 accession code for information on oxBS-seq data (used for Figure 7 and Supplemental Figures
717 8 and 9). The entirety of the RNA-sequencing data is available for download in FASTQ format
718 from NCBI Sequence Read Archive (GSE140895 and GSE140974). Other data that support the
719 findings of the study are available from the corresponding author (W.M.F.) upon reasonable
720 request.

721 **Statistics**

722 Datasets with groups of $n < 10$ were analyzed using GraphPad Prism version 8.2.0 (435) (San
723 Diego, CA) and represented as dot plots with underlying bar graph with mean \pm s.e.m. (standard
724 error of the mean) or box plots consisting of median (boxes spanning Q1–Q3 and whiskers to
725 the maximum and minimum value). Further information on research design is available in the
726 Nature Research Reporting Summary linked to this article and in **Supplementary Table 6**.

727 **Author contributions**

728 Ana J. Chucair-Elliott: co-first author, design of the work, execution of experiments, data
729 acquisition, analysis, and interpretation, figure generation, manuscript writing and preparation

730 Sarah R. Ocanas: co-first author, design of the work, execution of experiments, data acquisition,
731 analysis, and interpretation, figure generation, manuscript writing and preparation

732 David R. Stanford: data analysis

733 Victor A. Ansere: execution of experiments, data acquisition, and analysis

734 Kyla B. Buettner: execution of experiments, data acquisition, and analysis

735 Hunter Porter: data analysis

736 Nicole L. Eliason: execution of experiments, data acquisition, and analysis

737 Justin Reid: execution of experiments, data acquisition, and analysis

738 Amanda L. Sharpe: conceptual design of the study, data interpretation, manuscript writing

739 Michael B. Stout: conceptual design of the study, data interpretation, manuscript writing

740 Michael J. Beckstead: conceptual design of the study, data interpretation, manuscript writing

741 Benjamin F. Miller: conceptual design of the study, data interpretation, manuscript writing

742 Arlan Richardson: conceptual design of the study, data interpretation, manuscript writing

743 Willard M. Freeman: Corresponding author, conceptual design of the study, data analysis and
744 interpretation, figure generation, manuscript writing, preparation, and submission.

745 **Competing Interest statements**

746 Ana J. Chucair-Elliott: None

747 Sarah R. Ocanas: None

748 David R. Stanford: None

749 Victor A. Ansere: None

750 Kyla B. Buettner: None

751 Hunter Porter: None

752 Nicole L. Eliason: None

753 Justin Reid: None

754 Amanda L. Sharpe: None

755 Michael B. Stout: None

756 Michael J. Beckstead: None

757 Benjamin F. Miller: None

758 Arlan Richardson: None


759 Willard M. Freeman: None

760 References


- 761 1. Lister, R., *et al.* Global epigenomic reconfiguration during mammalian brain development.
762 *Science* **341**, 1237905 (2013).
- 763 2. Mo, A., *et al.* Epigenomic Signatures of Neuronal Diversity in the Mammalian Brain. *Neuron* **86**,
764 1369-1384 (2015).
- 765 3. Ayata, P., *et al.* Epigenetic regulation of brain region-specific microglia clearance activity. *Nat*
766 *Neurosci* **21**, 1049-1060 (2018).
- 767 4. Luo, C., *et al.* Single-cell methylomes identify neuronal subtypes and regulatory elements in
768 mammalian cortex. *Science* **357**, 600-604 (2017).
- 769 5. Haimon, Z., *et al.* Re-evaluating microglia expression profiles using RiboTag and cell isolation
770 strategies. *Nat Immunol* **19**, 636-644 (2018).
- 771 6. van den Brink, S.C., *et al.* Single-cell sequencing reveals dissociation-induced gene expression in
772 tissue subpopulations. *Nat Methods* **14**, 935-936 (2017).
- 773 7. Angermueller, C., *et al.* Parallel single-cell sequencing links transcriptional and epigenetic
774 heterogeneity. *Nat Methods* **13**, 229-232 (2016).
- 775 8. Heiman, M., *et al.* A translational profiling approach for the molecular characterization of CNS
776 cell types. *Cell* **135**, 738-748 (2008).
- 777 9. Sanz, E., *et al.* Cell-type-specific isolation of ribosome-associated mRNA from complex tissues.
778 *Proc Natl Acad Sci U S A* **106**, 13939-13944 (2009).
- 779 10. Deal, R.B. & Henikoff, S. The INTACT method for cell type-specific gene expression and
780 chromatin profiling in *Arabidopsis thaliana*. *Nat Protoc* **6**, 56-68 (2011).
- 781 11. Roh, H.C., *et al.* Simultaneous Transcriptional and Epigenomic Profiling from Specific Cell Types
782 within Heterogeneous Tissues In Vivo. *Cell Rep* **18**, 1048-1061 (2017).
- 783 12. Srinivasan, R., *et al.* New Transgenic Mouse Lines for Selectively Targeting Astrocytes and
784 Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo. *Neuron* **92**, 1181-1195
785 (2016).
- 786 13. Yona, S., *et al.* Fate mapping reveals origins and dynamics of monocytes and tissue macrophages
787 under homeostasis. *Immunity* **38**, 79-91 (2013).
- 788 14. Chucair-Elliott, A.J., *et al.* Tamoxifen induction of Cre recombinase does not cause long-lasting or
789 sexually divergent responses in the CNS epigenome or transcriptome: implications for the design
790 of aging studies. *Geroscience* (2019).
- 791 15. Kantzer, C.G., *et al.* Anti-ACSA-2 defines a novel monoclonal antibody for prospective isolation of
792 living neonatal and adult astrocytes. *Glia* **65**, 990-1004 (2017).
- 793 16. Sun, W., *et al.* SOX9 Is an Astrocyte-Specific Nuclear Marker in the Adult Brain Outside the
794 Neurogenic Regions. *J Neurosci* **37**, 4493-4507 (2017).
- 795 17. Verkhratsky, A. & Nedergaard, M. Physiology of Astroglia. *Physiol Rev* **98**, 239-389 (2018).
- 796 18. McKenzie, A.T., *et al.* Brain Cell Type Specific Gene Expression and Co-expression Network
797 Architectures. *Sci Rep* **8**, 8868 (2018).
- 798 19. Boisvert, M.M., Erikson, G.A., Shokhirev, M.N. & Allen, N.J. The Aging Astrocyte Transcriptome
799 from Multiple Regions of the Mouse Brain. *Cell Rep* **22**, 269-285 (2018).
- 800 20. Itoh, N., *et al.* Cell-specific and region-specific transcriptomics in the multiple sclerosis model:
801 Focus on astrocytes. *Proc Natl Acad Sci U S A* **115**, E302-E309 (2018).
- 802 21. O'Koren, E.G., Mathew, R. & Saban, D.R. Fate mapping reveals that microglia and recruited
803 monocyte-derived macrophages are definitively distinguishable by phenotype in the retina. *Sci*
804 *Rep* **6**, 20636 (2016).
- 805 22. Aguzzi, A., Barres, B.A. & Bennett, M.L. Microglia: scapegoat, saboteur, or something else?
806 *Science* **339**, 156-161 (2013).

- 807 23. Yeh, H. & Ikezu, T. Transcriptional and Epigenetic Regulation of Microglia in Health and Disease.
808 *Trends Mol Med* **25**, 96-111 (2019).
- 809 24. Sabbagh, M.F., *et al.* Transcriptional and epigenomic landscapes of CNS and non-CNS vascular
810 endothelial cells. *Elife* **7**(2018).
- 811 25. Hadad, N., *et al.* Absence of genomic hypomethylation or regulation of cytosine-modifying
812 enzymes with aging in male and female mice. *Epigenetics Chromatin* **9**, 30 (2016).
- 813 26. Wen, L., *et al.* Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base
814 resolution in the human brain. *Genome Biol* **15**, R49 (2014).
- 815 27. Masser, D.R., *et al.* Analysis of DNA modifications in aging research. *Geroscience* **40**, 11-29
816 (2018).
- 817 28. de Koning, A.P., Gu, W., Castoe, T.A., Batzer, M.A. & Pollock, D.D. Repetitive elements may
818 comprise over two-thirds of the human genome. *PLoS Genet* **7**, e1002384 (2011).
- 819 29. Papin, C., *et al.* Combinatorial DNA methylation codes at repetitive elements. *Genome Res* **27**,
820 934-946 (2017).
- 821 30. Bennett, M.L., *et al.* New tools for studying microglia in the mouse and human CNS. *Proc Natl*
822 *Acad Sci U S A* **113**, E1738-1746 (2016).
- 823 31. Clarke, L.E., *et al.* Normal aging induces A1-like astrocyte reactivity. *Proc Natl Acad Sci U S A* **115**,
824 E1896-E1905 (2018).
- 825 32. Zamanian, J.L., *et al.* Genomic analysis of reactive astrogliosis. *J Neurosci* **32**, 6391-6410 (2012).
- 826 33. Kielian, T. Toll-like receptors in central nervous system glial inflammation and homeostasis. *J*
827 *Neurosci Res* **83**, 711-730 (2006).
- 828 34. Cheray, M. & Joseph, B. Epigenetics Control Microglia Plasticity. *Front Cell Neurosci* **12**, 243
829 (2018).
- 830 35. Busch, R., Neese, R.A., Awada, M., Hayes, G.M. & Hellerstein, M.K. Measurement of cell
831 proliferation by heavy water labeling. *Nat Protoc* **2**, 3045-3057 (2007).
- 832 36. Reu, P., *et al.* The Lifespan and Turnover of Microglia in the Human Brain. *Cell Rep* **20**, 779-784
833 (2017).
- 834 37. Guneykaya, D., *et al.* Transcriptional and Translational Differences of Microglia from Male and
835 Female Brains. *Cell Rep* **24**, 2773-2783 e2776 (2018).
- 836 38. Ogilvy, S., *et al.* Promoter elements of *vav* drive transgene expression in vivo throughout the
837 hematopoietic compartment. *Blood* **94**, 1855-1863 (1999).
- 838 39. Chucair-Elliott, A.J., Carr, M.M. & Carr, D.J.J. Long-term consequences of topical dexamethasone
839 treatment during acute corneal HSV-1 infection on the immune system. *J Leukoc Biol* **101**, 1253-
840 1261 (2017).
- 841 40. Chucair-Elliott, A.J., Gurung, H.R., Carr, M.M. & Carr, D.J.J. Colony Stimulating Factor-1 Receptor
842 Expressing Cells Infiltrating the Cornea Control Corneal Nerve Degeneration in Response to HSV-
843 1 Infection. *Invest Ophthalmol Vis Sci* **58**, 4670-4682 (2017).
- 844 41. Chucair-Elliott, A.J., *et al.* Microglia-induced IL-6 protects against neuronal loss following HSV-1
845 infection of neural progenitor cells. *Glia* **62**, 1418-1434 (2014).
- 846 42. Habib, N., *et al.* Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat Methods* **14**,
847 955-958 (2017).
- 848 43. Lopez-Sanchez, N. & Frade, J.M. Genetic evidence for p75NTR-dependent tetraploidy in cortical
849 projection neurons from adult mice. *J Neurosci* **33**, 7488-7500 (2013).
- 850 44. Masser, D.R., Stanford, D.R. & Freeman, W.M. Targeted DNA methylation analysis by next-
851 generation sequencing. *J Vis Exp* (2015).
- 852 45. Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence
853 data. *Bioinformatics* **30**, 2114-2120 (2014).


- 854 46. Krueger, F. & Andrews, S.R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq
855 applications. *Bioinformatics* **27**, 1571-1572 (2011).
- 856 47. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357-
857 359 (2012).
- 858 48. Akalin, A., *et al.* methylKit: a comprehensive R package for the analysis of genome-wide DNA
859 methylation profiles. *Genome Biol* **13**, R87 (2012).
- 860 49. Gu, Z., Eils, R., Schlesner, M. & Ishaque, N. EnrichedHeatmap: an R/Bioconductor package for
861 comprehensive visualization of genomic signal associations. *BMC Genomics* **19**, 234 (2018).
- 862 50. Casper, J., *et al.* The UCSC Genome Browser database: 2018 update. *Nucleic Acids Res* **46**, D762-
863 D769 (2018).
- 864 51. Heiman, M., Kulicke, R., Fenster, R.J., Greengard, P. & Heintz, N. Cell type-specific mRNA
865 purification by translating ribosome affinity purification (TRAP). *Nat Protoc* **9**, 1282-1291 (2014).
- 866 52. Kang, S.S., *et al.* Microglial translational profiling reveals a convergent APOE pathway from
867 aging, amyloid, and tau. *J Exp Med* **215**, 2235-2245 (2018).
- 868 53. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome Biol*
869 **11**, R106 (2010).
- 870 54. Zhang, Y., *et al.* An RNA-sequencing transcriptome and splicing database of glia, neurons, and
871 vascular cells of the cerebral cortex. *J Neurosci* **34**, 11929-11947 (2014).
- 872 55. Tasic, B., *et al.* Adult mouse cortical cell taxonomy revealed by single cell transcriptomics.
873 *Nature Neuroscience* **19**, 335 (2016).
- 874 56. Zeisel, A., *et al.* Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq.
875 *Science* **347**, 1138-1142 (2015).
- 876 57. Simpson, J.T., *et al.* Detecting DNA cytosine methylation using nanopore sequencing. *Nature*
877 *Methods* **14**, 407 (2017).
- 878 58. Masser, D.R., *et al.* Hippocampal subregions exhibit both distinct and shared transcriptomic
879 responses to aging and nonneurodegenerative cognitive decline. *J Gerontol A Biol Sci Med Sci*
880 **69**, 1311-1324 (2014).
- 881 59. Miller, B.F., Drake, J.C., Naylor, B., Price, J.C. & Hamilton, K.L. The measurement of protein
882 synthesis for assessing proteostasis in studies of slowed aging. *Ageing Res Rev* **18**, 106-111
883 (2014).




884 **Figure 1. Flow cytometry and immunohistochemical validation of the Aldh111-NuTRAP**
 885 **transgene expression.** One week after Tam treatment, brains were harvested from Aldh111-
 886 NuTRAP and cre negative NuTRAP⁺ (control) mice for flow cytometry (FC) and
 887 immunohistochemistry (IHC) purposes. A) Representative FC plots of immunostained single- cell
 888 suspensions showed a distinct population of brain EGFP⁺ cells, identified as Aldh111⁺ cells
 889 (astrocyte lineage), based on gating strategy for EGFP and ACSA-2 co-expression in Aldh111-
 890 NuTRAP samples but not in the controls. B) Analysis of absolute cell counts from FC quantitation
 891 expressed as mean cell count/brain sample \pm SEM. C) Representative confocal fluorescent
 892 microscopy images of sagittal brain sections show EGFP expression (green signal) in cells that
 893 co-expressed mCherry (red signal) and GFAP (blue signal) in Aldh111-NuTRAP brains but did not
 894 colocalize with other cell type marker expression. *** $p < 0.001$ between depicted groups by one-
 895 way ANOVA followed by the Tukey's multiple comparison test (n=4 for cre⁺ group, n=3 for cre⁻
 896 group).



897 **Figure 2. Transcriptomic validation of astrocytic enrichment in TRAP-RNA from Aldh111-**
 898 **NuTRAP mouse brain.** A) TRAP-isolated RNA from input, TRAP-negative and TRAP-positive
 899 fractions were examined by qPCR for enrichment and depletion of selected cell-specific genes
 900 for astrocytes, microglia, neurons, and oligodendrocytes. Bar graphs represent mean relative
 901 gene expression \pm SEM for each gene measured. *, **and *** $p < 0.05$, $p < 0.01$, $p < 0.001$,
 902 respectively by one-way ANOVA with Benjamini-Hochberg multiple testing correction followed by
 903 Tukey's multiple comparison test across fractions ($n=3$ /group). B) RNAseq analysis was
 904 performed on all fractions and total brain RNA ($n=3$ /group). Principal component analysis of
 905 transcriptome profiles showed separation of positive fraction from input, negative, and tissue
 906 samples by the first component. C) Expression of cell-type marker gene lists, generated from cell
 907 sorting studies shows enrichment of astrocytic genes and depletion of other cell type genes in the
 908 positive fraction versus other fractions. D) Enrichment or depletion of marker genes is presented
 909 as the fold change (Positive fraction/Input). Astrocyte marker genes were enriched in the positive
 910 fraction while genes from other cell types were generally depleted in the positive fraction relative
 911 to input. E) Astrocyte marker genes identified in prior Ribo-Tag analysis (FC>5 Positive
 912 fraction/Input) with the same cre line (Srinivasan)¹² and with a Gfap-Cre line (Boisevert)¹⁹ were
 913 compared to the marker genes identified from the Aldh111-NuTRAP, demonstrating 127
 914 ribosomal-tagging common astrocyte marker genes. F) The 127 astrocyte markers were then
 915 compared to astrocyte markers from cell sorting studies (McKenzie et al., 2018)¹⁸ to identify 12
 916 isolation method independent astrocyte markers.




917 **Figure 3. Validation of astrocytic nuclei and epigenome enrichment in the Aldh111-NuTRAP**
 918 **mouse brain by INTACT-BSAS.** A) Representative confocal fluorescent microscopy images
 919 from input, negative, and positive INTACT nuclei fractions. B) Purity of astrocytic nuclei,
 920 expressed as average percentage \pm SEM mCherry⁺/ Biotin⁺ nuclei in the positive fraction,
 921 compared to percentage \pm SEM mCherry⁺ nuclei in the input demonstrates a high degree of
 922 specificity to the INTACT isolation (n=3/group, ***p<0.001 by paired T test comparing positive
 923 fraction to input). C) INTACT-isolated genomic DNA from Aldh111-NuTRAP mice was bisulfite
 924 converted and DNA methylation in specific regions of interest (promoters for neuron, astrocytes
 925 and microglia marker genes) were analyzed by Bisulfite Amplicon Sequencing (BSAS) from input,
 926 negative, and positive fractions. Hypomethylation of the Fabp7 astrocyte marker gene in the
 927 positive fraction compared to input and negative fraction correlates with astrocytic enrichment
 928 (average % mCG \pm SEM), as observed by RNA-seq (D), expressed as average normalized gene
 929 expression \pm SEM. n=4/group in C and n=3/group in D. ***p<0.001, **p<0.01 by one-way ANOVA
 930 followed by the Tukey's multiple comparison test.




931 **Figure 4. Flow cytometry and immunohistochemical validation of the Cx3cr1-NuTRAP**
 932 **mouse brain.** After Tam treatment, brains from Cx3cr1-NuTRAP and cre negative NuTRAP⁺
 933 (control) mice were harvested and single hemispheres assessed by flow cytometry (FC) and
 934 immunohistochemistry (IHC). A) Representative FC plots of immunostained single-cell
 935 suspensions showed a distinct population of brain EGFP⁺ cells, identified as CD11b⁺ cells
 936 (microglia lineage), based on gating strategy for EGFP and CD11b co-expression in Cx3cr1-
 937 NuTRAP samples upon cre-mediated recombination but not in the controls. B) Analysis of


938 absolute cell counts from FC quantitation expressed as mean cell count/brain sample \pm SEM. C)
939 Representative confocal fluorescent microscopy images of sagittal brain sections. EGFP
940 expression (green signal) was found in cells that co-expressed mCherry (red signal) and CD11b
941 (blue signal) in Cx3cr1-NuTRAP⁺ brains. * $p < 0.05$ between depicted groups by one-way ANOVA
942 followed by the Tukey's multiple comparison test (n=3/group).



943 **Figure 5. Validation of microglial TRAP-RNA enrichment in the Cx3cr1-NuTRAP mouse**
 944 **brain.** A) TRAP-isolated RNA from input, negative, and positive fractions were examined by
 945 qPCR for enrichment/depletion of selected cell-specific genes for microglia, astrocytes,
 946 oligodendrocytes, and neurons. Bar graphs represent average relative gene expression \pm SEM.
 947 *, ** and *** $p < 0.05$, $p < 0.01$, $p < 0.001$, respectively by one-way ANOVA with Benjamini-Hochberg
 948 procedure to correct for multiple comparisons of genes followed by Tukey's multiple comparison
 949 test of fractions ($n=6$ /group). B) Principal component analysis of transcriptome profiles showed
 950 separation of positive fraction from input, negative and tissue samples by the first component. C)
 951 RNAseq heatmap graph of cell type marker genes from prior cell sorting studies shows
 952 enrichment of microglial marker genes and depletion of other cell type markers, as compared to
 953 whole tissue, input, and negative fractions. D) Marker gene lists for different cell types were
 954 generated from cell sorting studies as described in the text. Enrichment or depletion of genes
 955 from each of the lists is presented as the fold change (Positive fraction/Input). Microglial marker
 956 genes were enriched in the positive fraction while genes from other cell types were generally
 957 depleted in the positive fraction relative to input. E) Microglia marker genes with $FC > 5$ (Positive
 958 fraction/Input) from the Cx3cr1-cre/ERT2⁺ model with RiboTag (Haimon)⁵, Cx3cr1-cre/ERT2⁺
 959 model with TRAP (Ayata)³, and NuTRAP identifies 142 ribosomal-tagging common microglial
 960 marker genes. F) Comparison of the 142 common microglial markers with previously identified
 961 microglial markers from cell sorting studies (McKenzie)¹⁸ identifies 101 isolation method-
 962 independent microglia marker genes.




963 **Figure 6. Validation of microglial epigenome enrichment in the Cx3cr1-NuTRAP mouse**
 964 **brain by INTACT-BSAS.** A) Representative confocal fluorescent microscopy images from input,
 965 negative, and positive INTACT nuclei fractions. B) Purity of microglial nuclei expressed as
 966 average percentage \pm SEM mCherry⁺/ Biotin⁺ nuclei in the positive fraction, and percentage \pm
 967 SEM mCherry⁺ nuclei in the input and average percentage \pm SEM mCherry⁺/Biotin⁺ nuclei in the
 968 input demonstrates a high degree of specificity to the INTACT isolation (n=5/group, ***p<0.001
 969 by paired T test comparing positive fraction to input). C) INTACT-isolated genomic DNA from
 970 Cx3cr1- NuTRAP mice was bisulfite converted and DNA methylation in specific regions of interest
 971 (promoters for neuron, astrocytes and microglia marker genes) were analyzed by Bisulfite
 972 Amplicon Sequencing (BSAS) from input, negative, and positive fractions. C) Hypomethylation of
 973 the Gpr84 microglial marker gene in the positive fraction compared to input and negative fraction
 974 correlates with microglial enrichment (average % mCG \pm SEM), as observed by RNA-seq,
 975 expressed as average normalized gene expression \pm SEM. D) n=4/group in C and n=6/group in
 976 D, **p<0.01, ***p<0.001, by one-way ANOVA followed by the Tukey's multiple comparison test.



977 **Figure 7. DNA modification profiles of INTACT isolated DNA from Aldh111-NuTRAP and**
 978 **Cx3cr1-NuTRAP mouse brains by WGoBS.** INTACT-DNA samples from Aldh111-NuTRAP
 979 and Cx3cr1-NuTRAP brains were used for epigenome analyses. A-D) Total genomic levels of
 980 mCG, hmCG, mCH, and hmCH ($n=8/\text{input}$, $n=4/\text{positive fraction}$; One-way ANOVA with Tukey's
 981 multiple comparisons test, $*p<0.05$, $**p<0.01$, $***p<0.001$). E) mCG averaged over 200 nucleotide
 982 bins upstream, in the gene body, and downstream of published astrocyte genes (McKenzie)¹⁸
 983 in the positive fraction of Aldh111-NuTRAP, positive fraction of Cx3cr1-NuTRAP, and input samples
 984 combined. F) Average percentage mCG in the positive fraction of Aldh111-NuTRAP, positive
 985 fraction of Cx3cr1-NuTRAP, and input samples combined in genomic DNA upstream 4kb of the
 986 TSS, in the gene body, and downstream 4kb of the TES of astrocytic genes G) Hypomethylation
 987 of astrocytic gene promoters in the Aldh111-NuTRAP positive fraction correlates with higher

988 astrocytic gene expression in the Aldh1l1 positive fraction than input and Cx3cr1-NuTRAP
989 positive fraction. H) mCG averaged over 200 nucleotide bins upstream, in the gene body, and
990 downstream of published microglia genes¹⁸ in the positive fraction of Aldh1l1-NuTRAP, positive
991 fraction of Cx3cr1-NuTRAP, and input. I) Average percentage mCG in the positive fraction of
992 Aldh1l1-NuTRAP, positive fraction of Cx3cr1-NuTRAP, and input DNA upstream 4kb of the TSS,
993 in the gene body, and downstream 4kb of the TES of microglia genes. J) Hypomethylation of
994 microglia gene promoters in the Cx3cr1 positive fraction correlates with higher microglia gene
995 expression. E-F-G-I) n=8/input, n=4/positive fraction; 2-way ANOVA with Sidak's multiple
996 comparison test, *p<0.05, **p<0.01, ***p<0.001.



997 **Figure 8. RNAseq analysis of microglial transcriptome and targeted BSAS in specific gene**
 998 **promoters 24 hours after LPS challenge in Cx3cr1-NuTRAP mouse brain.** Cx3cr1-NuTRAP
 999 mice were treated with LPS or PBS as control for 24 hours. A) RNAseq was performed and
 1000 principal component analysis of transcriptome profiles showed separation of positive fraction
 1001 (PBS- and LPS-treated) from input (PBS- and LPS-treated) samples by the first component, as
 1002 well as subclustering based on treatment within input and positive fraction samples by the second
 1003 component. B) Fold change of genes differentially expressed after LPS in the positive fraction
 1004 were compared to the fold change in the positive fraction. LPS induced larger changes when
 1005 microglial RNA is isolated by TRAP. C) RNAseq heatmap graph of cell type marker genes from

1006 prior cell sorting studies shows hierarchical clustering differentiating input from positive fractions
1007 and secondly comparing treatment within type of fraction. D-E) Tlr2 and Myd88 promoter
1008 methylation (mCG) decreases with LPS challenge in the positive fraction but not in the input, in
1009 correlation with increased Tlr2 and Myd88 gene expression in the positive fraction, as shown by
1010 RNAseq analysis. F) Although Ly96 promoter methylation decreases in the positive fraction with
1011 LPS challenge, there is no change in gene expression with LPS challenge in the input or positive
1012 fraction by RNA-seq. BSAS: n=4/group for Tlr2 and n=7/group for Ly96 and Myd88. RNA-seq:
1013 n=4/PBS groups, n=4/LPS input group, and n=5/LPS positive fraction group. *p<0.05, **p<0.01,
1014 ***p<0.001 by Multiple t-test with Holm-Sidak correction for multiple comparisons.